Get to know our clinical trials
Extension trial for post-trial access to remibrutinib.
THE OBJECTIVE OF THIS TRIAL IS TO PROVIDE CONTINUED TREATMENT WITH REMIBRUTINIB AND COLLECT LONG-TERM SAFETY DATA IN PATIENTS WHO HAVE COMPLETED A NOVARTIS REMIBRUTINIB TRIAL, WHO HAVE BENEFITED FROM TREATMENT, AND WHO CANNOT OBTAIN REMIBRUTINIB LOCALLY.
Status
In recruitment
headquarters
Madrid
Technical Summary
- CLINICAL TRIAL TO PROVIDE ACCESS TO REMIBRUTINIB AFTER THE TRIAL ENDS AND TO COLLECT INFORMATION ON LONG-TERM SAFETY IN PATIENTS WHO HAVE COMPLETED TREATMENT WITH REMIBRUTINIB IN A NOVARTIS TRIAL.
- Code EudraCT: 2025-524078-4000
- Protocol number: CLOU064A2306B
- Promoter: Novartis Farmaceutica
- Molecule/Drug: Remibrutinib
- Link to Clinical Trials
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.